Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
Meta Found Liable in New Mexico Facebook Data Privacy Case 
DaVoice Sues Perplexity AI Over Trade Secrets 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
AMD Hits $1 Trillion as BofA Raises Price Target to $720 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
Dollar Holds Near Two-Month High as Yen Approaches 160 
Apple Extends Qualcomm Patent Licensing Deal 
OpenAI Agent Breaches Australia Medicare Data Portal 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
Tesla Semi Rollout Begins at Nevada Factory 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Japanese Bank Stocks Surge as Bond Yields Fuel Rate Hike Bets 
Add as a preferred source on Google
Merck & Co. is said to be in advanced talks for the acquisition of Seagen, a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Fox Business reported that the acquisition deal could be valued at almost $40 billion. The amount could be more as the share price for Seagen is above $200 per share. The deal will help Merck & Co. with its expansion efforts as it adds a new acquisition to its cancer drug portfolio.
Currently, Merck’s highest-selling product is its Keytruda immunotherapy drug. The Rahway, New Jersey pharmaceutical company said that this drug accounted for $17.2 billion worth of its sales last year. As for Seagen, some of its best-selling products include Adcetris, which gathered total sales of $1.4 billion last year.
In any case, while Merck and Seagen are already in the advanced stage of negotiations, it was noted that there is still no assurance that they will be reaching an agreement for the sale of the latter.
Moreover, it was mentioned that any proposed deal in this negotiation is also expected to draw a close look from antitrust regulators. Both Merck and Seagen are still hoping to finally sign an agreement on or before Merck announces its second fiscal-quarter earnings, which has been scheduled for July 28.
Reuters reached out to Merck for comments regarding the acquisition reports, but it was not able to respond to the request immediately. On the other hand, Seagen was said to have declined to comment.
As of Wednesday, July 6, the companies are still discussing a price above $200 per share, and on that day, its closing share price was actually $175. It was added that Seagen has a market capitalization of $32.24 billion based on the records from Refinitiv data.
Meanwhile, industry observers believe that it will make sense if Merck & Co. is able to close its deal with Seagen for $250 or below. This is because this acquisition will definitely boost the company’s business and strengthen its portfolio through the latter’s exclusive cancer immunotherapy drug, Keytruda.
